The use of the CRISPR/Cas9 technology in the development of animal producers of human recombinant proteins in the projects of the world-class research and educational centre “Innovative Solutions in the Agro-Industrial Complex”

A. V. Deikin¹, V. O. Soldatov², M. V. Korokin³, S. V. Nadezhdin³, L. M. Danilenko³, A. L. Kulikov³, O. A. Puchenkova³, M. V. Pokrovskii^1,3
1Belgorod world-class Scientific and Educational Center “Innovative Solutions in the Agro-Industrial Complex”, Sobornaya pl., 4, Belgorod, 308005, Russian Federation
²Institute of Gene Biology, Russian Academy of Sciences, Core Facility Centre “Genome editing”, ul. Vavilova, 34/5, Moskva, 119334, Russian Federation
³Belgorod State National Research University (NRU “BelSU”), Research Institute of Pharmacology of Living Systems, ul. Pobedy, 85, Belgorod, 308015, Russian Federation

Abstract. Abstract. The development of transgenic organisms opens up a number of areas of their biomedical use, which include the production of recombinant human proteins for replacement, pathogenetic, and etiological treatment of a wide range of diseases. Genomic editing for breeding farm animals as producers of humanized proteins is a promising biotechnological direction. Systems based on the use of ZNF and TALEN nucleases specifically bind to the target genomic DNA sequence to create a double-stranded break in it. The damaged area is restored through homologous or random repair. The advantages of this genomic editing technology include high specificity and a low percentage of off-target interactions, and the disadvantages are the high cost of recombinant ZNF and TALEN nucleases. Due to the high specificity and predictability of the effect, it is generally more applicable to solving medical problems. The CRISPR/Cas9 system is based on the complementary interaction of sgRNA and the target genomic DNA region. Thus, it is simpler and cheaper. Its use is more justified in scientific research and in working with animals. Today, there are all scientific and economic reasons to think that genomic editing using CRISPR/Cas9 will lead to significant qualitative changes in the agricultural sector. The situation in this area is improved by the gradual easing of the regulatory policy on genetically modified animals.

Keywords: CRISPR/Cas9; animal producers; recombinant proteins; biotechnology; biomedicine.

Author Details: A. V. Deikin, Cand. Sc. (Biol.), research fellow; V. O. Soldatov, junior research fellow; M. V. Korokin, D. Sc. (Med.), assoc. prof.; S. V. Nadezhdin, Cand. Sc. (Biol.), research fellow; L. M. Danilenko, D. Sc. (Pharm.), assoc. prof.; A. L. Kulikov, research fellow; O. A. Puchenkova, student; M. V. Pokrovskii, D. Sc. (Med.), prof., director (e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра.).

For citation: Deikin AV, Soldatov VO, Korokin MV, et al. [The use of the CRISPR/Cas9 technology in the development of animal producers of human recombinant proteins in the projects of the world-class research and educational centre “Innovative Solutions in the Agro-Industrial Complex”]. Dostizheniya nauki i tekhniki APK. 2020;34(9):25-9. Russian. doi: 10.24411/0235-2451-2020-10905.